ArticleCureus2024
A Rare Case of Congenital Factor XIII Deficiency Secondary to Hyperconsumption: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired Factor XIII (FXIII) deficiency is a rare condition often associated with underlying medical conditions or medications. We present a case of a 23-year-old male, who presented with prolonged bleeding from a traumatic ulcer site on his left leg. Initial laboratory investigations revealed a severe deficiency in FXIII activity (30%) and antigen levels (25%), with no evidence of congenital disorders or other underlying pathologies. Further evaluation indicated a pattern of hyperconsumption due to ongoing bleeding episodes in the form of excessive use of clotting factors due to repeated bleeding episodes and impaired clot stability, leading to a coagulopathy where factors are consumed faster than they can be produced. The patient was treated with six units of cryoprecipitate to address the bleeding and was started on high-end antibiotics, including meropenem and vancomycin, to manage a suspected septic process. This comprehensive approach led to significant clinical improvement, with the resolution of symptoms and stabilization of the ulcer site. This case highlights the importance of considering acquired FXIII deficiency in patients with unexplained bleeding diathesis, especially in the context of alcohol abuse or conditions associated with hyperconsumption. Early recognition and immediate treatment are crucial for improving prognostic outcomes for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.